These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37310509)

  • 21. HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development.
    Hu J; Liu K; Luo J
    Cancer Treat Res; 2019; 177():231-250. PubMed ID: 30523627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of antiviral activities of four local Malaysian Phyllanthus species against herpes simplex viruses and possible antiviral target.
    Tan WC; Jaganath IB; Manikam R; Sekaran SD
    Int J Med Sci; 2013; 10(13):1817-29. PubMed ID: 24324358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.
    Susser S; Flinders M; Reesink HW; Zeuzem S; Lawyer G; Ghys A; Van Eygen V; Witek J; De Meyer S; Sarrazin C
    Antimicrob Agents Chemother; 2015 May; 59(5):2746-55. PubMed ID: 25712364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era.
    Maida I; Ríos MJ; Pérez-Saleme L; Ramos B; Soriano V; Pegram PS; Mura MS; Sánchez-Margalet V; Saldívar-Cornejo I; Wilkin A; Babudieri S; Núñez M
    AIDS Res Hum Retroviruses; 2008 May; 24(5):679-83. PubMed ID: 18462085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection.
    Cheruvu S; Marks K; Talal AH
    Clin Liver Dis; 2007 Nov; 11(4):917-43, ix-x. PubMed ID: 17981235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress on global hepatitis elimination targets.
    Waheed Y
    World J Gastroenterol; 2021 Dec; 27(47):8199-8200. PubMed ID: 35068864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of human immunodeficiency virus on viral hepatitis.
    Mallet V; Vallet-Pichard A; Pol S
    Liver Int; 2011 Jan; 31 Suppl 1():135-9. PubMed ID: 21205151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells.
    Pollock S; Nichita NB; Böhmer A; Radulescu C; Dwek RA; Zitzmann N
    Proc Natl Acad Sci U S A; 2010 Oct; 107(40):17176-81. PubMed ID: 20855621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chemical constituents of Phyllanthus urinaria L. and its antiviral activity against hepatitis B virus].
    Zhong Y; Zuo C; Li F; Ding X; Yao Q; Wu K; Zhang Q; Wang Z; Zhou LW; Lan J; Wang X
    Zhongguo Zhong Yao Za Zhi; 1998 Jun; 23(6):363-4, 384. PubMed ID: 11601301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro.
    Jung J; Kim NK; Park S; Shin HJ; Hwang SG; Kim K
    BMC Complement Altern Med; 2015 Jul; 15():255. PubMed ID: 26220282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Covalent Antiviral Agents.
    Mirzaie S; Abdi F; GhavamiNejad A; Lu B; Wu XY
    Adv Exp Med Biol; 2021; 1322():285-312. PubMed ID: 34258745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistent Replication of HIV, Hepatitis C Virus (HCV), and HBV Results in Distinct Gene Expression Profiles by Human NK Cells.
    Boeijen LL; Hou J; de Groen RA; Verbon A; Boonstra A
    J Virol; 2019 May; 93(9):. PubMed ID: 30185599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection.
    Hofmann WP; Soriano V; Zeuzem S
    Handb Exp Pharmacol; 2009; (189):321-46. PubMed ID: 19048206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus.
    Ely A; Arbuthnot P
    Discov Med; 2015 Sep; 20(109):137-43. PubMed ID: 26463095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings.
    Easterbrook P; Sands A; Harmanci H
    Semin Liver Dis; 2012 May; 32(2):147-57. PubMed ID: 22760654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in antiviral agents: antiviral drug discovery for hepatitis viruses.
    Tanikawa K
    Curr Pharm Des; 2006; 12(11):1371-7. PubMed ID: 16611121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis.
    Soriano V; Barreiro P; Martín-Carbonero L; Castellares C; Ruiz-Sancho A; Labarga P; Ramos B; Gonzalez-Lahoz J
    J Infect Dis; 2007 Apr; 195(8):1181-3. PubMed ID: 17357055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.
    Nguyen MH; Wong G; Gane E; Kao JH; Dusheiko G
    Clin Microbiol Rev; 2020 Mar; 33(2):. PubMed ID: 32102898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.